公开(公告)号：BR9812127A

公开(公告)日：2000-07-18

申请号：BR9812127

申请日：1998-08-10

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  TEODOZYJKOLASA ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J

IPC: C07D237/14 ,  C07D237/18 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/06 ,  C07D409/06 ,  C07D409/12 ,  C07D417/06 ,  A61K31/50 ,  C07D413/06 ,  C07F11/00

公开(公告)号：NO20000863D0

公开(公告)日：2000-02-22

申请号：NO20000863

申请日：2000-02-22

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J

IPC: C07D237/14 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/5377 ,  A61P5/00 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D20060101 ,  C07D237/10 ,  C07D237/16 ,  C07D237/18 ,  C07D237/20 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07F9/547 ,  C07F9/6509 ,  C07F11/00 ,  C07D

Abstract: In the present invention, there are described pyridazinone compounds, which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1), which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：NO20000863A

公开(公告)日：2000-02-22

申请号：NO20000863

申请日：2000-02-22

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J

IPC: C07D237/14 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/5377 ,  A61P5/00 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D20060101 ,  C07D237/10 ,  C07D237/16 ,  C07D237/18 ,  C07D237/20 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07F9/547 ,  C07F9/6509 ,  C07F11/00

CPC classification number: C07D401/06 ,  C07D237/14 ,  C07D237/18 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/06 ,  C07D409/06 ,  C07D409/12 ,  C07D417/06

公开(公告)号：CA2327185A1

公开(公告)日：1999-10-14

申请号：CA2327185

申请日：1999-04-08

Applicant: ABBOTT LAB

Inventor： SCIOTTI RICHARD J ,  GUBBINS EARL J ,  LULY JAY R ,  ZHOU XUN ,  TU NOAH P ,  WIEDEMAN PAUL E ,  WARRIOR USHA ,  DJURIC STEVAN W ,  MADAR DAVID J ,  BA MAUNG NWE Y ,  BASHA ANWER ,  WAGENAAR FRANK L

IPC: C07D231/12 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/42 ,  A61K31/422 ,  A61K31/425 ,  A61K31/433 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/454 ,  A61K31/475 ,  A61P17/00 ,  A61P17/06 ,  A61P29/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07D231/14 ,  C07D231/16 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D409/10 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D417/10 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04 ,  C07D231/00 ,  C07D333/00

Abstract: Compounds having formula (I) are useful for treating diseases that are prevented by or ameliorated with Interleukin-2, Interleukin-4, or Interleukin5 production inhibitors.

公开(公告)号：ES2131185T3

公开(公告)日：1999-07-16

申请号：ES94902209

申请日：1993-11-05

Applicant: ABBOTT LAB

Inventor： BASHA ANWER ,  BHATIA PRAMILA ,  BROOKS DEE W ,  CRAIG RICHARD A ,  RATAJCZYK JAMES D ,  STEWART ANDREW O

IPC: A61K31/17 ,  A61K31/38 ,  A61K31/381 ,  A61K31/425 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4433 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P17/00 ,  A61P25/00 ,  A61P27/16 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07C273/18 ,  C07C275/24 ,  C07C275/64 ,  C07D213/61 ,  C07D277/28 ,  C07D307/52 ,  C07D333/20 ,  C07D333/22 ,  C07D405/06 ,  C07D409/04 ,  C07D409/06 ,  C07D417/04 ,  C07C275/20

Abstract: PCT No. PCT/US93/10675 Sec. 371 Date Apr. 13, 1995 Sec. 102(e) Date Apr. 13, 1995 PCT Filed Nov. 5, 1993 PCT Pub. No. WO94/11342 PCT Pub. Date May 26, 1994The invention relates to compounds having activity to inhibit lipoxygenase enzyme activity, to pharmaceutical compositions comprising these compounds, and to a medical method of treating. More particularly, this invention concerns certain substituted arylalkynyl- and ((heteroaryl)alkynyl)-N-hydroxy-ureas which inhibit leukotriene biosynthesis, to pharmaceutical compositions of these compounds and to a method of inhibiting leukotriene biosynthesis.

公开(公告)号：CA2578858A1

公开(公告)日：1999-03-04

申请号：CA2578858

申请日：1998-08-10

Applicant: ABBOTT LAB

Inventor： MCCARTY CATHERINE M ,  PATEL MEENA V ,  LIU HUAQING ,  KORT MICHAEL E ,  KOLASA TEODOZYJ ,  BLACK LAWRENCE A ,  BASHA ANWER ,  ROHDE JEFFREY J

IPC: C07D237/14 ,  A61K31/50 ,  A61K31/501 ,  C07D237/18

公开(公告)号：MX9204051A

公开(公告)日：1993-08-01

申请号：MX9204051

申请日：1991-07-11

Applicant: ABBOTT LAB

Inventor： BROOKS DEE W ,  STEWART ANDREW O ,  KERKMAN DANIEL J ,  BHATIA PRAMILA A ,  BASHA ANWER ,  MARTIN JONATHAN G

IPC: A61K31/44

公开(公告)号：AU2004274492B2

公开(公告)日：2010-04-29

申请号：AU2004274492

申请日：2004-09-17

Applicant: ABBOTT LAB

Inventor： BUNNELLE WILLIAM H ,  DART MICHAEL J ,  TIETJE KARIN R ,  SCHRIMPF MICHAEL R ,  RYTHER KEITH B ,  GALLAGHER MEGAN E ,  NERSESIAN DIANA L ,  MORTELL KATHLEEN H ,  PACE JENNIFER M ,  BASHA ANWER ,  JI JIANGUO

IPC: A61K31/435 ,  A61P25/00 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08

Abstract: Compounds of formula (I) Z-Ar 1 -Ar 2 wherein Z is a diazabicyclic amine, Ar 1 is a 5- or 6-membered aromatic ring, and Ar 2 is selected from the group consisting of an unsubstituted or substituted 5-or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazoyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by ±7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

公开(公告)号：SK286972B6

公开(公告)日：2009-08-06

申请号：SK2312000

申请日：1998-08-10

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J

IPC: C07D237/00 ,  C07D237/14 ,  A61K31/00 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/5377 ,  A61P5/00 ,  A61P19/00 ,  A61P19/02 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P43/00 ,  C07D20060101 ,  C07D237/10 ,  C07D237/16 ,  C07D237/18 ,  C07D237/20 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07F9/547 ,  C07F9/6509 ,  C07F11/00

Abstract: Described are pyridazinone compounds of formula (I) which are cyclooxygenase inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2), which is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：CZ300570B6

公开(公告)日：2009-06-17

申请号：CZ20011481

申请日：1999-10-27

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFEY J ,  COGHLAN MICHAEL J ,  STEWART ANDREW O

IPC: C07D237/14 ,  A61K31/50 ,  A61K31/501 ,  A61P19/02 ,  A61P25/04 ,  A61P29/00 ,  A61P35/00 ,  C07D237/16 ,  C07D237/18 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/06

Abstract: Predložený vynález popisuje slouceniny pyridazinonu, které jsou inhibitory cyklooxygenasy (COX), zejména jsou selektivními inhibitory cylkooxygenasy-2 (Cox-2), Cox-2 je indukovatelná izoforma související se zánetem na rozdíl od konstitutivní izoformy, cyklooxygenasy-1 (Cox-1), která je duležitým "udržujícím" enzymem v mnoha tkáních, vcetne gastrointestinálního traktu (GI) a ledvin. Selektivita techto sloucenin pro Cox-2 minimalizuje nežádoucí vedlejší úcinky GI a renální oblasti, které jsou u bežne prodávaných, nesteroidních, protizánetlivých léciv (NSAID). Farmaceutická kompozice obsahující therapeuticky úcinné množství slouceniny a farmaceuticky prijatelný nosic. Použití této slouceniny pro výrobu léciva pro inhibici biosyntézy prostaglandinu u savce pri potrebe takového ošetrení. Použití slouceniny pro výrobu léciva pro ošetrení bolesti, horecky, zánetu, revmatické artritity, osteoartritidy, adheze a karcinomu.